Emerging treatments
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Yee AJ et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30375-8. doi: 10.1016/S1470-2045(16)30375-8. [Epub ahead of print]. A selective histone deacetylase inhibitor for myeloma. Pratt G et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30407-7. doi: 10.1016/S1470-2045(16)30407-7. [Epub ahead of print]. Vemurafenib in combination with cobimetinib in…